Infertility Services Market in US 2017-2021

不妊治療サービスの米国市場2017-2021

◆タイトル:Infertility Services Market in US 2017-2021
◆商品コード:IRTNTR12046
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年2月17日
◆ページ数:80
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥392,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥504,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥560,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、不妊治療サービスの米国市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、不妊治療サービスの米国市場規模及び予測、製品別分析、サービス別分析、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Infertility Services
Infertility is the failure to achieve pregnancy after 12 months of unprotected intercourse. Infertility occurs due to the abnormal functioning of the female and male reproductive system. It can be treated with infertility drugs and through procedures such as artificial insemination, in-vitro fertilization, and surrogacy.

Technavio’s analysts forecast the infertility services market in US to grow at a CAGR of 4.65% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the infertility services market in US for 2017-2021. To calculate the market size, the report considers the services carried out during treatment via infertility drugs and assisted reproductive technology (ART) services.

Technavio’s report, Infertility Services Market in US 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• CARE facility
• CooperSurgical
• Ferring Pharmaceuticals
• Monash IVF
• Merck
• Vitrolife

[Other prominent vendors]
• AbbVie
• Apricus Biosciences
• AstraZeneca
• Auxogyn
• Eli Lilly
• EMD Serono
• IKS International
• InVitro Care
• INVO Bioscience
• Irvine Scientific
• LifeGlobal
• MedITEX
• NMC Health
• OB GYN Associates
• OvaScience
• Pantec Biosolutions
• Reproductive Medicine Associates of New Jersey
• The Sims Clinic
• TriHealth
• Virtus Health
• Xytex Cryo International

[Market driver]
• Rising success rate of infertility treatments.
• For a full, detailed list, view our report

[Market challenge]
• Limited reimbursements and lack of strict regulatory oversight.
• For a full, detailed list, view our report

[Market trend]
• Upsurge in mergers and acquisitions.
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents

PART 01: Executive summary

PART 02: Scope of  the report

Market overview
Vendor analysis
Top-vendor offerings

PART 03: Market research methodology

Research methodology
Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Market landscape

Market overview
Market size and forecast
Five forces analysis

PART 06: Market segmentation by underlying cause

PART 07: Market segmentation by services

Market overview
ART services market in US
Infertility drugs services market in US

PART 08: Market drivers

PART 09: Impact of drivers

PART 10: Market challenges

PART 11: Impact of drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

Competitive scenario
Other prominent vendors

PART 14: Key Vendor Analysis

CARE Fertility
CooperSurgical
Ferring Pharmaceuticals
Monash IVF
Merck
Vitrolife

PART 15: Appendix

List of abbreviations

PART 16: Explore Technavio

[List of Exhibits]

Exhibit 01: US infertility services market segmentation: Overview

Exhibit 02: Product offerings

Exhibit 03: Assessment of regulatory bodies

Exhibit 04: Snapshot: Infertility services market in US

Exhibit 05: US fertility chart 2015

Exhibit 06: Stages of infertility treatment

Exhibit 07: Infertility services market in the US 2016-2021 ($ billions)

Exhibit 08: Side effects and success rates of infertility services in US

Exhibit 09: Impact of various factors on infertility services in US

Exhibit 10: Recommendations to vendors

Exhibit 11: Five forces analysis

Exhibit 12: Infertility services market in US by underlying cause

Exhibit 13: Diagnosis of infertility

Exhibit 14: Market segmentation by services 2016-2021(in %)

Exhibit 15: Snapshot: US fertility services market by product

Exhibit 16: Categories of ART services 2016

Exhibit 17: IVF overview

Exhibit 18: ART services market in US 2016-2021 ($ billions)

Exhibit 19: Comparison of fresh and frozen ART cycle

Exhibit 20: Infertility drugs services market in US 2016-2021($ billions)

Exhibit 21: Success rate of IVF procedures

Exhibit 22: ART procedures in US (in thousands)

Exhibit 23: Obesity prevalence in the US (2015)

Exhibit 24: Infertility rates by age

Exhibit 25: US birth rates by women

Exhibit 26: Impact of drivers

Exhibit 27: Cost breakdown of IVF by various stages in US

Exhibit 28: Impact of drivers and challenges

Exhibit 29: Notable M&A activity

Exhibit 30: Same sex married couples in US

Exhibit 31: CARE Fertility: Profile

Exhibit 32: CARE Fertility: Strength analysis

Exhibit 33: CARE Fertility: Strategy assessment

Exhibit 34: CARE Fertility: Opportunity assessment

Exhibit 35: CooperSurgical: Profile

Exhibit 36: CooperSurgical: Strength analysis

Exhibit 37: CooperSurgical: Growth strategy assessment

Exhibit 38: CooperSurgical: Opportunity assessment

Exhibit 39: Ferring Pharmaceuticals: Profile

Exhibit 40: Ferring Pharmaceuticals: Strength analysis

Exhibit 41: Ferring Pharmaceuticals: Strategy assessment

Exhibit 42: Ferring Pharmaceuticals: Opportunity assessment

Exhibit 43: Monash IVF: Profile

Exhibit 44: Monash IVF: Strength analysis

Exhibit 45: Monash IVF: Strategy assessment

Exhibit 46: Monash IVF: Opportunity assessment

Exhibit 47: Merck: Profile

Exhibit 48: Merck: Strength analysis

Exhibit 49: Merck: Strategy assessment

Exhibit 50: Merck: Opportunity assessment

Exhibit 51: Vitrolife: Profile

Exhibit 52: Vitrolife: Strength analysis

Exhibit 53: Vitrolife: Strategy assessment

Exhibit 54: Vitrolife: Opportunity assessment



【資料のキーワード】

不妊治療サービス

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[不妊治療サービスの米国市場2017-2021] (Infertility Services Market in US 2017-2021 / IRTNTR12046)販売に関する免責事項
[不妊治療サービスの米国市場2017-2021] (Infertility Services Market in US 2017-2021 / IRTNTR12046)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆